In November 2025, the U.S. Food and Drug Administration (FDA) announced it will remove the long-standing “black box” warnings from most hormone replacement therapy (HRT) products that contain estrogen or estrogen-progestogen combinations.
For many women, this change represents a meaningful shift in how hormone therapy is understood, discussed, and approached — and we want to help explain what this update really means.
Why Were Black Box Warnings There in the First Place
The warnings were introduced in the early 2000s following results from the Women’s Health Initiative (WHI) study. That study raised concerns about potential risks such as breast cancer, cardiovascular disease, stroke, and dementia.
However, what’s important to know now is this:
- The study primarily included older women, with an average age of about 63
- Many participants were well past menopause
- The hormone formulations used in the study differ from many modern HRT options
Subsequent research has shown that these findings do not apply in the same way to women who begin hormone therapy earlier in menopause.
What New Research Has Shown
Over the years, growing evidence has clarified that:
- Starting HRT within 10 years of menopause or before age 60 is associated with more favorable outcomes for many women
- Risks vary significantly based on age, timing, hormone type, dose, and delivery method
- Hormone therapy is not a one-size-fits-all treatment — and never should have been treated as one
Because of this evolving understanding, the FDA determined that the blanket warning no longer reflects current science for most women.
What This Means for Women Today
This change may have several important effects:
- Less fear and confusion around hormone therapy safety
- More open, individualized conversations between women and their healthcare providers
-Greater access to effective treatment for symptoms such as:
- Hot flashes and night sweats
- Sleep disruption
- Mood changes
- Vaginal dryness
- Bone loss and fracture risk
Some clinicians believe this shift may help women address menopausal symptoms earlier, potentially improving quality of life and long-term health.
How Blackburn Drug Supports Individualized Care
At Blackburn Drug, we work closely with prescribers to support evidence-based, personalized hormone therapy.
As a compounding pharmacy, we can provide:
- Custom hormone strengths
- Alternative dosage forms
- Personalized delivery methods
- Options when commercial products don’t meet a patient’s needs
Our role is to support thoughtful, individualized care — helping women and providers navigate both the science and the practical details of hormone therapy.
If you have questions about hormone therapy or how this change may apply to you, we encourage you to speak with your healthcare provider — and know that Blackburn Drug is here to support that conversation.
